6 citations
,
July 2025 in “Cancer Medicine” This study reported that ZSYY001, a nanoparticle formulation of polymeric micellar paclitaxel, showed promising antitumor activity and was safe and well-tolerated in preclinical models and a phase I trial, without acute hypersensitivity reactions at doses up to 390 mg/m².
November 2005 in “CRC Press eBooks” This article reviews the development and challenges of skin penetration enhancers, highlighting their limitations in compatibility and safety, and reports no new clinical findings.
65 citations
,
February 2011 in “Molecular cancer therapeutics” This study reported that the novel AKT inhibitor CCT128930 demonstrated significant antitumor activity in human cancer cell lines and xenografts, highlighting its potential as an anticancer therapy.
16 citations
,
December 2022 in “Expert Opinion on Drug Delivery” This study reviewed preclinical and clinical research and found that AFL-assisted topical drug delivery is considered safe and effective, enhancing drug efficacy, reducing treatment time and pain, and improving cosmetic and safety outcomes, but larger clinical trials are needed to confirm these benefits.
142 citations
,
March 2019 in “Frontiers in Cellular Neuroscience” This review discusses the development and potential therapeutic applications of adenosine receptor agonists and positive allosteric modulators, noting that while many clinical trials have been unsuccessful, initial results for new compounds are promising.